TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life
Brief Summary: The aim of the study is to assess whether PTH (1-84) therapy posses advantages compared to conventional treatment in patients with hypoparathyroidism on muscle function, quality of life, calcium homeostasis, bone metabolism, and body composition.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50, 75, 100 mcg NPSP558; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NPSP558; Assigned to Arm(s): 50, 75, 100 mcg NPSP558
B: Intervention Type: DRUG; Name: Synthetic Human Parathyroid Hormone 1-34; Assigned to Arm(s): N/A
C: Arm Label: a: PTH (1-84) 100 ug s.c.inj. once a day; Type: ACTIVE_COMPARATOR; Interventions: Drug: a: PTH (1-84) | Arm Label: b: placebo 100 ug s.c. inj. once a day; Type: PLACEBO_COMPARATOR; Interventions: Drug: b:placebo | Intervention Type: DRUG; Name: a: PTH (1-84); Assigned to Arm(s): a: PTH (1-84) 100 ug s.c.inj. once a day | Intervention Type: DRUG; Name: b:placebo; Assigned to Arm(s): b: placebo 100 ug s.c. inj. once a day
D: Arm Label: 25 µg dose; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Arm Label: 50 µg dose; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Intervention Type: DRUG; Name: NPSP558; Assigned to Arm(s): 25 µg dose, 50 µg dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study
Brief Summary: Is VAX125 safe at doses ranging from 0.1 to 8 ug when delivered i.m. in a single dose regimen Is VAX125 able to induce a post-vaccination serum HAI antibody response in healthy adults against the influenza A virus H1 HA.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: VAX125 | Intervention Type: BIOLOGICAL; Name: VAX125; Assigned to Arm(s): A
B: Arm Label: vaccine; Type: EXPERIMENTAL; Interventions: Biological: Non-adjuvanted A(H1N1)v influenza vaccine | Intervention Type: BIOLOGICAL; Name: Non-adjuvanted A(H1N1)v influenza vaccine; Assigned to Arm(s): vaccine
C: Arm Label: Trivalent influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
D: Arm Label: cohort I; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort II; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort III; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort IV; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort V; Type: OTHER; Interventions: Biological: GHB01L1 | Intervention Type: BIOLOGICAL; Name: GHB01L1; Assigned to Arm(s): cohort I, cohort II, cohort III, cohort IV, cohort V

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation to Assess the Effect of the Combination of a Pre-Defined Management Pathway to Reduce Fluid Overload in Cardiac Decompensation With Carelink Remote Management, Connexus Remote Telemetry and the OptiVol Early Warning System on Health Care Utilization
Brief Summary: This pilot study is to prospectively evaluate the benefit of clinicians being able to access ICD device information in a timelier manner and treat fluid overload with a pre-defined pattern using the Medtronic OptiVol, Medtronic CareAlerts and Medtronic CareLink in Conexus-enabled devices (remote arm) as compared to the same devices without Medtronic OptiVol, Medtronic CareAlerts and Medtronic CareLink available to the treating physician (standard arm).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Directed Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Call-Center Directed (CCD) Weight Loss Program | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Directed (IPD) Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Call-Center Directed (CCD) Weight Loss Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: In-Person Directed (IPD) Weight Loss Program; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Self-Directed Weight Loss Program; Assigned to Arm(s): 1
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: telemedicine | Intervention Type: OTHER; Name: telemedicine; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Device triggered remote telephone contact because of Care Alert | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Device triggered remote telephone contact because of Care Alert; Assigned to Arm(s): 1
D: Arm Label: Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice, Behavioral: Poor weather forecast warning | Arm Label: No Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD self care advice; Assigned to Arm(s): Forecast, No Forecast | Intervention Type: BEHAVIORAL; Name: Poor weather forecast warning; Assigned to Arm(s): Forecast

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Liver Resection With or Without Vascular Inflow Occlusion: a Randomized Control Trial
Brief Summary: This study aims to evaluate whether applying inflow vascular occlusion in modern liver resection is associated with better clinical outcome.

Eligible patients are randomly assigned to the two surgical techniques: with or without the application of inflow vascular occlusion.

Patients outcome including liver function recovery, operative time and blood loss are compared.


Options:
A: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Intermittent Pringle maneuver | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Intermittent Pringle maneuver; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Normovolemic Hemodilution (ANH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of care | Intervention Type: PROCEDURE; Name: Normovolemic Hemodilution (ANH); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard of care; Assigned to Arm(s): 2
D: Arm Label: Standard fluid management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard fluid management | Arm Label: Goal directed fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Goal directed fluid therapy with the Edwards EV1000 system | Intervention Type: PROCEDURE; Name: Standard fluid management; Assigned to Arm(s): Standard fluid management | Intervention Type: DEVICE; Name: Goal directed fluid therapy with the Edwards EV1000 system; Assigned to Arm(s): Goal directed fluid therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV
Brief Summary: This is an open Phase I study of a candidate TB vaccine, MVA85A, in healthy subjects who are infected with HIV. It is designed to study the safety and immunogenicity of the vaccine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 1, 2
B: Intervention Type: BIOLOGICAL; Name: MVA 85A; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: BCG (SSI Strain); Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: MVA85A (Tuberculosis vaccine); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solar Water Disinfections: Randomized Intervention Trial
Brief Summary: The importance of waterborne gastrointestinal illness throughout the developing world, the existence of a cheap and effective intervention (SODIS), the concurrent limited dissemination program for SODIS, the need for a controlled evaluation of the effectiveness of SODIS under actual field conditions, and the experience of our tri-national collaborative research team in successfully conducting large scale drinking water intervention and observational studies in both the United States and the developing world encourage us to propose the following randomized controlled trial in which our specific aims are to:

* Evaluate the hypothesis that SODIS reduces the incidence of gastrointestinal illness in 660 children under the age of five years in rural Bolivia that are randomly selected from 22 villages ;
* Define, through an extensive microbiologic testing component, the baseline rates of pathogen-specific diarrheal illnesses and the pathogens responsible for the differences in diarrheal illness between active and control groups;
* Document the actual use and acceptance of SODIS by participants in the study;
* Assess the cost-effectiveness of SODIS and the social and economic impact of SODIS at household level;
* Examine through mathematical disease modelling the effects of the presence of multiple transmission pathways within a village on the preventable fraction estimate due to the introduction of SODIS.


Options:
A: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Solar Water Disinfection (SODIS) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Solar Water Disinfection (SODIS); Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Brief Summary: The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population


Options:
A: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Brief Summary: The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population


Options:
A: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Brief Summary: The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population


Options:
A: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700
C: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
D: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism
Brief Summary: Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.


Options:
A: Arm Label: a: PTH (1-84) 100 ug s.c.inj. once a day; Type: ACTIVE_COMPARATOR; Interventions: Drug: a: PTH (1-84) | Arm Label: b: placebo 100 ug s.c. inj. once a day; Type: PLACEBO_COMPARATOR; Interventions: Drug: b:placebo | Intervention Type: DRUG; Name: a: PTH (1-84); Assigned to Arm(s): a: PTH (1-84) 100 ug s.c.inj. once a day | Intervention Type: DRUG; Name: b:placebo; Assigned to Arm(s): b: placebo 100 ug s.c. inj. once a day
B: Arm Label: 25 µg dose; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Arm Label: 50 µg dose; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Intervention Type: DRUG; Name: NPSP558; Assigned to Arm(s): 25 µg dose, 50 µg dose
C: Intervention Type: DRUG; Name: Synthetic Human Parathyroid Hormone 1-34; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50, 75, 100 mcg NPSP558; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NPSP558; Assigned to Arm(s): 50, 75, 100 mcg NPSP558

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters
Brief Summary: The aim of the study is to determine whether physiological sex steroid replacement improves parameters of skeletal, cardiovascular and reproductive health of women treated with current sex steroid replacement regimens.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: 4 mg estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol | Arm Label: 2 mg estradiol; Type: PLACEBO_COMPARATOR; Interventions: Drug: estradiol | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): 2 mg estradiol, 4 mg estradiol
C: Intervention Type: DRUG; Name: Growth Hormone (Humatrope); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ethinylestradiol / Norethisterone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol / Progesterone | Intervention Type: DRUG; Name: Ethinylestradiol / Norethisterone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Estradiol / Progesterone; Assigned to Arm(s): 2

Answer: D